Results 41 to 50 of about 165,965 (304)

Adipocyte Myoglobin Is a Determinant of Energy Expenditure and a Potential Target to Limit Obesity

Advanced Science, EarlyView.
Myoglobin, known as a muscle oxygen‐carrying protein, is shown to play a key role in fat cells that burn energy. Loss of myoglobin reduces the body's ability to generate heat and increases obesity risk, while restoring it improves metabolism. The study identifies myoglobin as a regulator of fat burning and a potential target to enhance energy ...
Christian Strehlau, Helen Broghammer, Claudia Gebhardt, Anne Hoffmann, Tobias Hagemann, Şeyma Midilli, Rachel S. Zimmer, Kristin Schubert, Vasiliki Karagiannakou, Anastasia Georgiadi, Mario Ost, Martin Krüger, Lisa Roth, Kerstin Krause, Nora Klöting, Maria Keller, Martin Wabitsch, Rima Nuwayhid, Roland H. Stimson, Michael Stumvoll, Matthias Blüher, Juliane Weiner, John T. Heiker   +22 more
wiley   +1 more source

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

International Journal of Molecular Sciences, 2023
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment.
R. Nevola, R. Epifani, S. Imbriani, G. Tortorella, C. Aprea, R. Galiero, L. Rinaldi, R. Marfella, F. Sasso   +8 more
semanticscholar   +1 more source

GLP-1 receptor agonists for Parkinson's disease

Cochrane Database of Systematic Reviews, 2020
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney, Gonçalo S, Duarte, Joel, Handley, David Jw, Evans, Suresh, Menon, Richard, Wyse, Hedley Ca, Emsley   +6 more
openaire   +3 more sources

Adverse Effects of GLP-1 Receptor Agonists [PDF]

The Review of Diabetic Studies, 2014
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos, Thalia V, Panagiotopoulou, Moses S, Elisaf   +2 more
openaire   +2 more sources

Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies

Advanced Science, EarlyView.
This review delineates the hypothalamic circuits that control liver homeostasis via autonomic and neuroendocrine pathways. Dysregulation of this hypothalamus–liver axis drives disease progression across a spectrum including steatotic liver disease, liver inflammation and injury, fibrosis, cirrhosis, and hepatocellular carcinoma.
Qin Tang, Jiahui Li, Haiying Song, Ailin Zhang, Haifeng Zeng, Yining Xu, Li Mo, Jinhan He   +7 more
wiley   +1 more source

Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy

JAMA Internal Medicine, 2023
Key Points Question Is periconceptional use of glucagon-like peptide 1 (GLP-1) receptor agonists or other noninsulin second-line antidiabetic medications (ADMs) associated with increased risk of major congenital malformations? Findings This multinational
C. Cesta, R. Rotem, B. Bateman, Gabriel Chodick, J. Cohen, K. Furu, M. Gissler, K. Huybrechts, L. Kjerpeseth, M. Leinonen, L. Pazzagli, H. Zoega, E. Seely, E. Patorno, S. Hernández-Díaz   +14 more
semanticscholar   +1 more source

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.

The Lancet Diabetes and Endocrinology
BACKGROUND GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain.
S. Badve, A. Bilal, Matthew M Y Lee, N. Sattar, H. Gerstein, Christian T. Ruff, John J. V. McMurray, P. Rossing, G. Bakris, Kenneth W Mahaffey, J. Mann, Helen M. Colhoun, K. Tuttle, R. Pratley, V. Perkovic   +14 more
semanticscholar   +1 more source

The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.

The American journal of geriatric psychiatry, 2023
AIM/HYPOTHESIS Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may exert positive effects in patients with depression. Our aim was to conduct a systematic review and meta-analysis to examine the antidepressant effects
Xinda Chen, Peiyi Zhao, Weihao Wang, Lixin Guo, Q. Pan   +4 more
semanticscholar   +1 more source

GLP-1 Receptor Agonists and Kidney Protection

Medicina, 2019
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR).
Eulalia Greco, Giuseppina Russo, Annalisa Giandalia, Francesca Viazzi, Roberto Pontremoli, Salvatore De Cosmo   +5 more
openaire   +3 more sources